<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271698</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00055895</org_study_id>
    <nct_id>NCT02271698</nct_id>
  </id_info>
  <brief_title>Dexamethasone and Pain Following Total Knee Arthroplasty</brief_title>
  <official_title>Perioperative Dexamethasone to Promote Systemic Pro-Resolution Phenotype for Prevention of Acute and Chronic Pain Post-Total Knee Arthroplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is three fold. First to determine the ideal dose of dexamethasone
      intraoperatively that will reduce acute pain and opioid consumption. Second determine if
      dexamethasone at the time of surgery reduces chronic pain following total knee arthroplasty
      and finally determine if a pro-inflammatory environment makes patients susceptible to chronic
      pain after surgery and can dexamethasone alter this environment. Patients undergoing total
      knee arthroplasty will be randomized to four groups ( 0mg, 6mg, 12mg and 24mg dexamethasone)
      and assessments will be made of acute and chronic pain and quality of life measures. Blood
      samples will be drawn to assess Interleukin levels and for Macrophage sorting. For the
      primary efficacy endpoint of reduction of opioid consumption over 24 hours after surgery the
      dexamethasone regimen group will be compared to standard of care group using t-test. For
      comparisons of the secondary efficacy endpoints, t-test, Chi-square test and Fisher's Exact
      test will be used. Risks of this study include the risks of venipuncture and intravenous
      dexamethasone administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV single center, prospective, randomized, double-blind, dose response study
      designed to evaluate the optimum dose of dexamethasone to administer as an analgesic in total
      knee arthroplasty surgery. Randomization will be performed using computer software and the
      randomization order will be written and enclosed in envelopes in the study office. A total of
      40 patients will be randomized to receive different doses of dexamethasone intravenously at
      induction of anesthesia with the same dose repeated 24 hours later. The dose groups are: 0mg,
      6mg, 12mg, 24mg. The groups will be evenly divided into 10 subjects in each group. Patients
      will be cared for using established standard of care anesthetic and multi modal analgesia
      pathway used clinically at Duke University Medical Center. Knee arthroplasty generally occurs
      in patients over 65 years of age and an inclusion criteria is age 55 years or older is
      included in the study. Regional anesthesia is more technically challenging in morbidly obese
      patients. Because of an increased failure rate of regional anesthesia in morbidly obese
      patients an upper limit BMI of 40 is included in the study design.

      Anesthetic regime. The anesthesia will be standard of care apart from the administration of
      the study drug.

      Study Drug. After randomization the first dose of intravenous dexamethasone will be
      administered by the anesthesia care team immediately before surgery. The subject and study
      personnel will be blinded to the dose. The patient will be sedated and the study personnel
      will not be in the operating room. The dose will be recorded on the anesthesia record.

      The second dose of dexamethasone will be prescribed by the PI. This will be prescribed
      electronically to be administered to the subject on the floor 24 hours after the first dose.

      Surgery The surgery will proceed normally with no difference for the study.

      Postoperative Pain Management Patients in all groups will receive standard of care
      postoperative analgesic regimen.

      Blood Samples Blood will be drawn in preop holding (Time 0) for Interleukin 6, Interleukin10
      and for macrophage sorting.

      Blood samples will be repeated for Interleukin 6 and Interleukin10 at 10-14, 22-26 and
      33-39hours after surgery.

      Blood samples for macrophage sorting will be repeated at 33-39hours. The total blood
      collected will be 30ml on the day of surgery and 10 ml post operative day 1 for an overall
      total of 40cc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analogue Pain Score</measure>
    <time_frame>6, 12, 18, 24, 36 hours after surgery</time_frame>
    <description>Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where &quot;0&quot; represents no pain and &quot;10&quot; represents worst pain ever.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Opioid Consumption</measure>
    <time_frame>6, 12, 18, 24, 36 hours after surgery</time_frame>
    <description>mg of morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index</measure>
    <time_frame>30 days, 3 and 6 months following surgery</time_frame>
    <description>The Western Ontario and McMaster Universities Osteoarthritis Index measures 17 items for functional limitation (score range 0-68). Higher score = higher difficulty with the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire</measure>
    <time_frame>Baseline at enrollment, 3 months and 6 months after surgery</time_frame>
    <description>Brief pain inventory questionnaire will be administered generating a score (0-40). Higher scores reflect higher perceived pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status as Measured by Brief Pain Inventory Questionnaire</measure>
    <time_frame>Baseline at Enrollment, 3 and 6 months after surgery</time_frame>
    <description>Brief pain inventory questionnaire will be administered generating a score (0-70). Higher scores reflect higher perceived pain interference.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Macrophage Proliferation</measure>
    <time_frame>Samples will be taken immediately pre incision and will be repeated at 33-39hours</time_frame>
    <description>Macrophage totals and differentiation will be assessed within patients and between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Interleukin 6 and 10 Levels</measure>
    <time_frame>Sample immediately prior to incision and at 10-14, 22-26 and 33-39hours after surgery.</time_frame>
    <description>Interleukin levels and the ratio will assess pro and anti inflammatory processes in the patients</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Acute Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 6mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 12mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 24mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
    <arm_group_label>Dexamethasone 6mg</arm_group_label>
    <arm_group_label>Dexamethasone 12mg</arm_group_label>
    <arm_group_label>Dexamethasone 24mg</arm_group_label>
    <other_name>Dexamethasone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo unilateral total knee arthroplasty.

          -  American Society of Anesthesiology (ASA) Physical Class 1-3.

          -  BMI &lt;40 kg/m2

        Exclusion Criteria:

          -  Revision surgery.

          -  Bilateral total knee arthroplasty.

          -  Unicompartmental knee arthroplasty.

          -  Patients with a contraindication to regional anesthesia. This includes abnormal
             clotting, skin infection in groin or near the back, the presence of neurological
             disorders or anatomical abnormalities of the vertebral column.

          -  Contraindications or known drug interactions with dexamethasone.

          -  Use of any of the following medications within the times specified before surgery:

               -  Long-acting opioid medication within 3 days.

               -  Any opioid medication within 24 hours.

          -  Body weight less than 50 kilograms (~110 pounds).

          -  Planned administration of another investigational product or procedure during the
             subject's participation in this study.

          -  Suspected, or known addiction to or abuse of illicit drug(s), prescription
             medicine(s), or alcohol within the past 2 years.

          -  Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the
             opinion of the Investigator, may interfere with study assessments or compliance.

          -  Current or historical evidence of any clinically significant disease or condition
             that, in the opinion of the Investigator, may increase the risk of surgery or
             complicate the subject's postoperative course.

          -  Significant medical conditions or laboratory results that, in the opinion of the
             Investigator, indicate an increased vulnerability to study drugs and procedures, and
             expose the subject to an unreasonable risk as a result of participating in this
             clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial
             or complete conduction block, impaired cardiac function (Ejection fraction under 35%),
             epilepsy, myasthenia gravis), severe renal impairment (creatinine &gt; 1.8), comorbid
             conditions associated with an immunocompromised status, such as blood dyscrasias,
             HIV/AIDS, or recent chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart A Grant, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DUMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee arthroplasty</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Acute pain</keyword>
  <keyword>Chronic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>45 participants signed consent. 3 participants withdrew prior to randomization</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone 6mg</title>
          <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone 12mg</title>
          <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="P3">
          <title>Dexamethasone 24mg</title>
          <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone 6mg</title>
          <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone 12mg</title>
          <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="B3">
          <title>Dexamethasone 24mg</title>
          <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.06" spread="8.74"/>
                    <measurement group_id="B2" value="66.56" spread="8.32"/>
                    <measurement group_id="B3" value="64.14" spread="6.43"/>
                    <measurement group_id="B4" value="69.45" spread="5.45"/>
                    <measurement group_id="B5" value="67.13" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analogue Pain Score</title>
        <description>Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where “0” represents no pain and “10” represents worst pain ever.</description>
        <time_frame>6, 12, 18, 24, 36 hours after surgery</time_frame>
        <population>Participants who completed pain score at specified time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 6mg</title>
            <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 12mg</title>
            <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone 24mg</title>
            <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analogue Pain Score</title>
          <description>Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where “0” represents no pain and “10” represents worst pain ever.</description>
          <population>Participants who completed pain score at specified time-points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hour at rest</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="1.45"/>
                    <measurement group_id="O2" value="4.80" spread="2.20"/>
                    <measurement group_id="O3" value="3.56" spread="2.74"/>
                    <measurement group_id="O4" value="5.5" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour with movement</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="2.42"/>
                    <measurement group_id="O2" value="6.50" spread="3.10"/>
                    <measurement group_id="O3" value="5.88" spread="2.47"/>
                    <measurement group_id="O4" value="7.33" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour at rest</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="1.99"/>
                    <measurement group_id="O2" value="3.50" spread="1.96"/>
                    <measurement group_id="O3" value="2.78" spread="1.86"/>
                    <measurement group_id="O4" value="5.18" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour with movement</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="2.25"/>
                    <measurement group_id="O2" value="6.11" spread="1.76"/>
                    <measurement group_id="O3" value="6.00" spread="2.77"/>
                    <measurement group_id="O4" value="7.30" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hour at rest</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="1.86"/>
                    <measurement group_id="O2" value="2.70" spread="2.45"/>
                    <measurement group_id="O3" value="2.56" spread="2.40"/>
                    <measurement group_id="O4" value="5.09" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hour with movement</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="3.16"/>
                    <measurement group_id="O2" value="5.43" spread="2.99"/>
                    <measurement group_id="O3" value="4.63" spread="2.88"/>
                    <measurement group_id="O4" value="6.90" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour at rest</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="2.34"/>
                    <measurement group_id="O2" value="3.50" spread="2.27"/>
                    <measurement group_id="O3" value="3.67" spread="2.65"/>
                    <measurement group_id="O4" value="4.09" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour with movement</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="2.68"/>
                    <measurement group_id="O2" value="6.50" spread="2.07"/>
                    <measurement group_id="O3" value="6.38" spread="2.33"/>
                    <measurement group_id="O4" value="7.20" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hour at rest</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.24"/>
                    <measurement group_id="O2" value="3.86" spread="2.54"/>
                    <measurement group_id="O3" value="4.43" spread="2.30"/>
                    <measurement group_id="O4" value="2.89" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hour with movement</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.60"/>
                    <measurement group_id="O2" value="7.00" spread="1.79"/>
                    <measurement group_id="O3" value="6.83" spread="2.23"/>
                    <measurement group_id="O4" value="6.33" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <p_value_desc>6 hour pain at rest</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>6 hour pain with movement</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>12 hour pain at rest</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.350</p_value>
            <p_value_desc>12 hour pain at rest</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>18 hour pain at rest</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.198</p_value>
            <p_value_desc>18 hour pain with movement</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hour pain at rest</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.228</p_value>
            <p_value_desc>24 hour pain with movement</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.457</p_value>
            <p_value_desc>36 hour pain at rest</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.394</p_value>
            <p_value_desc>36 hour pain with movement</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Opioid Consumption</title>
        <description>mg of morphine equivalents</description>
        <time_frame>6, 12, 18, 24, 36 hours after surgery</time_frame>
        <population>Participants who completed pain score at specified time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 6mg</title>
            <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 12mg</title>
            <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone 24mg</title>
            <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Opioid Consumption</title>
          <description>mg of morphine equivalents</description>
          <population>Participants who completed pain score at specified time-points.</population>
          <units>mg of morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.10" spread="15.94"/>
                    <measurement group_id="O2" value="22.20" spread="23.54"/>
                    <measurement group_id="O3" value="11.77" spread="11.75"/>
                    <measurement group_id="O4" value="33.50" spread="21.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.24" spread="50.16"/>
                    <measurement group_id="O2" value="27.24" spread="30.03"/>
                    <measurement group_id="O3" value="54.23" spread="35.80"/>
                    <measurement group_id="O4" value="32.25" spread="30.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.30" spread="16.77"/>
                    <measurement group_id="O2" value="16.86" spread="16.93"/>
                    <measurement group_id="O3" value="43.16" spread="55.34"/>
                    <measurement group_id="O4" value="29.75" spread="37.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" spread="15.69"/>
                    <measurement group_id="O2" value="20.91" spread="17.93"/>
                    <measurement group_id="O3" value="25.86" spread="14.80"/>
                    <measurement group_id="O4" value="23.79" spread="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.00" spread="25.22"/>
                    <measurement group_id="O2" value="24.61" spread="17.13"/>
                    <measurement group_id="O3" value="36.43" spread="26.25"/>
                    <measurement group_id="O4" value="21.29" spread="13.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <p_value_desc>6 hours</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.364</p_value>
            <p_value_desc>12 hours</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.605</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>18 hours</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>24 hours</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.600</p_value>
            <p_value_desc>36 hours</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index</title>
        <description>The Western Ontario and McMaster Universities Osteoarthritis Index measures 17 items for functional limitation (score range 0–68). Higher score = higher difficulty with the task.</description>
        <time_frame>30 days, 3 and 6 months following surgery</time_frame>
        <population>Participants who completed questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 6mg</title>
            <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 12mg</title>
            <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone 24mg</title>
            <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index</title>
          <description>The Western Ontario and McMaster Universities Osteoarthritis Index measures 17 items for functional limitation (score range 0–68). Higher score = higher difficulty with the task.</description>
          <population>Participants who completed questionnaire</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 Days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="18.5" upper_limit="34"/>
                    <measurement group_id="O2" value="29.5" lower_limit="21.25" upper_limit="38.75"/>
                    <measurement group_id="O3" value="42" lower_limit="33" upper_limit="43"/>
                    <measurement group_id="O4" value="30" lower_limit="23.5" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="12" upper_limit="23.5"/>
                    <measurement group_id="O2" value="32" lower_limit="24.5" upper_limit="40.25"/>
                    <measurement group_id="O3" value="19" lower_limit="12" upper_limit="35"/>
                    <measurement group_id="O4" value="24" lower_limit="12.25" upper_limit="33.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7.5" upper_limit="22.5"/>
                    <measurement group_id="O2" value="24.5" lower_limit="12.75" upper_limit="29.5"/>
                    <measurement group_id="O3" value="17" lower_limit="11.5" upper_limit="22"/>
                    <measurement group_id="O4" value="16" lower_limit="9" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire</title>
        <description>Brief pain inventory questionnaire will be administered generating a score (0-40). Higher scores reflect higher perceived pain.</description>
        <time_frame>Baseline at enrollment, 3 months and 6 months after surgery</time_frame>
        <population>Participants who completed questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 6mg</title>
            <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 12mg</title>
            <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone 24mg</title>
            <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire</title>
          <description>Brief pain inventory questionnaire will be administered generating a score (0-40). Higher scores reflect higher perceived pain.</description>
          <population>Participants who completed questionnaire</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O4" value="4" lower_limit="1.75" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="2" lower_limit="0.75" upper_limit="3"/>
                    <measurement group_id="O4" value="2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status as Measured by Brief Pain Inventory Questionnaire</title>
        <description>Brief pain inventory questionnaire will be administered generating a score (0-70). Higher scores reflect higher perceived pain interference.</description>
        <time_frame>Baseline at Enrollment, 3 and 6 months after surgery</time_frame>
        <population>Participants who completed questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone 6mg</title>
            <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone 12mg</title>
            <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O3">
            <title>Dexamethasone 24mg</title>
            <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status as Measured by Brief Pain Inventory Questionnaire</title>
          <description>Brief pain inventory questionnaire will be administered generating a score (0-70). Higher scores reflect higher perceived pain interference.</description>
          <population>Participants who completed questionnaire</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O3" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O4" value="4" lower_limit="1.75" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="5" lower_limit="2.25" upper_limit="8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O4" value="1.5" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4.75"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Macrophage Proliferation</title>
        <description>Macrophage totals and differentiation will be assessed within patients and between groups.</description>
        <time_frame>Samples will be taken immediately pre incision and will be repeated at 33-39hours</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Interleukin 6 and 10 Levels</title>
        <description>Interleukin levels and the ratio will assess pro and anti inflammatory processes in the patients</description>
        <time_frame>Sample immediately prior to incision and at 10-14, 22-26 and 33-39hours after surgery.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to 6 month follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone 6mg</title>
          <description>Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone 12mg</title>
          <description>Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="E3">
          <title>Dexamethasone 24mg</title>
          <description>Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>wound dehisence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urine retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stuart Alan Grant</name_or_title>
      <organization>Duke University Health System</organization>
      <phone>919-681-6437</phone>
      <email>stuart.grant@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

